CURRICULUM VITAE
Albert N. Bruno, M.D.
PRESENT POSITION
Urology Associates, LLC
2525 W. University Ave.
Suite 504
Muncie, IN 47303
Phone: (765) 289-7444
Fax: (765) 289-8628
1984-present
Active Clinical Staff
Ball Memorial Hospital
2401 W. University Ave.
Muncie, IN 47303
1984-present
PAST POSITION
Chairman
Surgery Department
Ball Memorial Hospital
2401 W. University Ave.
Muncie, IN 47303
1990-1991
CERTIFICATION
American Board of Urology
1988
UNDERGRADUATE EDUCATION
Rutgers University
Newark, New Jersey
BA Cum Laude
1973
GRADUATE MEDICAL EDUCATION
Jersey City Medical Center
Department of Surgery
Jersey City, New Jersey
1979-1980
UROLOGY RESIDENCY
Northeastern Ohio University College of Medicine
Dr. J.L. Summers
Department of Urology
Albert N. Bruno, M.D.
June 1 , 2006
Page 2 of 3
Akron City Hospital
Akron, OH
1981-1984
LICENSURE
Maine
1980
Ohio
1981
Indiana
1984
PROFESSIONAL AFFILIATIONS
American Urologic Association
American Association of Clinical Urologists
Indiana State Medical Association
PUBLICATIONS
Bruno, AN, Summers, JL. Ischemic Heart Disease in Patients with Large Gland Prostatic
Hypertrophy. Urology 25, 239 (1985).
Bruno, AN, Lavin, JP, Nasrallah, PF. Ultrasound Experience with Prenatal Genitourinary
Abnormalities. Urology 25, 196 (1985).
HONORS AND ACHIEVEMENTS
National Honor Society (1968-1969)
Graduated cum Laude, Rutgers University (1973)
Presentation of an original paper at the North Central Section AUA (Marco Island, FL, Oct. 1723, 1982)
Cleveland Urological Society, May 1983, Second Prize-Prenatal Ultrasound Experience with
Genitourinary Abnormalities
AREAS OF PROFESSIONAL INTEREST
Prosthesis in Urology
Pediatric Urology
Infertility
RESEARCH EXPERIENCE
ILEX Oncology, Inc.
Phase III Randomized, Double-Blind Study of DFMO vs.
Placebo in Low Grade Superficial Bladder Cancer.
Warner Chilcott Laboratories Urogenital Investigation with Estrace Cream. A Phase IV, OpenLabel, Multicenter, Community-Based Trial of Estrace Cream
for the Treatment of Urogenital Symptoms in Postmenopausal
Women.
Albert N. Bruno, M.D.
June 1 , 2006
Page 3 of 3
Schering
A Multicenter Trial of Induction and 6 courses of 3 week
Maintenance with BCG Versus BCG Plus Interferon Alpha-2b
(Intron A) in Superficial Bladder Cancer
Novartis
Protocol #CZOL446EUS24: An Open-Label Trial on the Effect
of IV Zometa 4 mg. on Bone Mineral Density in Hormone
Sensitive Prostate Cancer Patients with Bone Metastasis
Novartis
Protocol CZOL446G US45: The Effect of Zometa Compared to
Placebo on Bone Mineral Density in Patients Undergoing
Androgen Deprivation Therapy. Zenith Trial (CZOL446G
US45)
Hoosier Oncology
Group/CATO
Protocol GU02-41. A Phase III, Randomized, Double-Blind,
Placebo-Controlled Trial Evaluating the Ability of Risedronate to
Prevent Skeletal Related Events in Patients with Metastatic
Prostate Cancer Commencing Hormonal Therapy.
Yamanouchi
Protocol 905-UC-006: An Open-Label Study Multicenter Study
to Assess The Efficacy and Safety of Daily Oral Administration
of 5 and 10 mg Vesicare (Solifenacin Succinate) in Patients
Who Wish to Switch from Detrol LA® (Tolterodine Tartrate
Extended Release) for the Treatment of Overactive Bladder
Symptoms (VERSUS)
Amgen
Protocol 20040138: A Randomized, Double-Blind, Placebocontrolled Study to Evaluate AMG 162 in the Treatment of Bone
Loss in Subjects Undergoing Androgen-Deprivation Therapy for
Non-metastatic Prostate Cancer (HALT)
__________________________
Albert N. Bruno, M.D.
__________________
Date